All In Biotech

Drugs by condition

Drugs approved for hypertrophic cardiomyopathy

Brand-name prescription drugs and biologics whose FDA label lists hypertrophic cardiomyopathy as an approved use. Matched on the label phrases: "hypertrophic cardiomyopathy".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

2

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

2

New molecular entities and new biologics

In development

2

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for hypertrophic cardiomyopathy.

  • Myqorzo (Aficamten) · Cytokinetics NovelBreakthrough therapyOrphanDec 19, 2025
  • Camzyos (Mavacamten) · Bristol NovelBreakthrough therapyOrphanApr 28, 2022

All approved drugs for hypertrophic cardiomyopathy, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Cardiac Myosin Inhibitor (1)

  • Camzyos Mavacamten · Bristol · 2022

Class not listed in FDA's data (1)

  • Myqorzo Aficamten · Cytokinetics · 2025

Drugs in development for hypertrophic cardiomyopathy

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • HRS-1893Phase 35 trials

    Shandong Suncadia Medicine Co., Ltd. · Obstructive Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy

  • EDG-7500Phase 21 trial

    Edgewise Therapeutics, Inc. · Hypertrophic Cardiomyopathy

More on hypertrophic cardiomyopathy: recruiting trials · published research

Related in cardiovascular and metabolic: Type 2 diabetes · Type 1 diabetes · Obesity and weight management · High blood pressure (hypertension) · Heart failure · High cholesterol · High triglycerides · Atrial fibrillation · Blood clots (DVT and pulmonary embolism) · Stroke prevention

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.